Patents by Inventor Joseph P. Vacca

Joseph P. Vacca has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200392106
    Abstract: Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.
    Type: Application
    Filed: July 16, 2020
    Publication date: December 17, 2020
    Inventors: Joseph P. Vacca, Dansu Li, Sarah Elizabeth Bettigole
  • Publication number: 20200383984
    Abstract: Provided herein are heteroaryl compounds, for example, a compound of Formula I or IA, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, ameliorating, or preventing one or more symptoms of a disorder, disease, or condition mediated by a casein kinase 1 (CK1), an interleukin-1 receptor associated kinase (IRAK1), or a cyclin-dependent kinase 9 (CDK9).
    Type: Application
    Filed: February 7, 2019
    Publication date: December 10, 2020
    Inventors: Irit Snir-Alkalay, Joseph P. Vacca, Yinon Ben-Neriah
  • Publication number: 20200270211
    Abstract: Herein, compounds, compositions and methods for modulating inclusion formation and stress granules in cells related to the onset of neurodegenerative diseases, musculoskeletal diseases, cancer, ophthalmological diseases, and viral infections are described.
    Type: Application
    Filed: December 22, 2017
    Publication date: August 27, 2020
    Inventors: Duane A. Burnett, Joseph P. Vacca
  • Patent number: 10745379
    Abstract: Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: August 18, 2020
    Assignee: Cornell University
    Inventors: Joseph P. Vacca, Dansu Li, Sarah Bettigole
  • Publication number: 20200157079
    Abstract: Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.
    Type: Application
    Filed: August 16, 2019
    Publication date: May 21, 2020
    Applicant: Quentis Therapeutics, Inc.
    Inventors: Joseph P. Vacca, Dansu Li, Sarah Bettigole
  • Patent number: 10654852
    Abstract: The present invention includes novel 3,6-diazabicyclo[3.1.1]heptane antibiotic compounds and any salts or solvates thereof. The present invention further includes methods of preparing such compounds, and methods of treating bacterial infection in a subject using such compounds.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: May 19, 2020
    Assignee: THE BROAD INSTITUTE, INC.
    Inventor: Joseph P. Vacca
  • Patent number: 10562909
    Abstract: Provided herein are substituted fused quadracyclic compounds useful as inhibitors of MK2. The invention further provides pharmaceutical compositions of the compounds of the invention. The invention also provides medical uses of substituted fused quadracyclic compounds.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: February 18, 2020
    Assignee: Tabomedex Biosciences, LLC
    Inventors: Casey C. McComas, Michael H. Serrano-Wu, Joseph P. Vacca
  • Publication number: 20200048277
    Abstract: The present application provides compounds that modulate CDK protein function. Methods of making the compounds, compositions containing the compounds, and uses of the compounds for treating or ameliorating of diseases, disorders, or conditions associated with CDK proteins, are also disclosed.
    Type: Application
    Filed: July 25, 2019
    Publication date: February 13, 2020
    Inventors: Kyle W.H. Chan, Aparajita Hoskote Chourasia, Paul E. Erdman, Leah Fung, David Aaron Hecht, Frank Mercurio, Robert Sullivan, Joseph P. Vacca
  • Publication number: 20190276434
    Abstract: Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.
    Type: Application
    Filed: December 1, 2017
    Publication date: September 12, 2019
    Applicant: Quentis Therapeutics, Inc.
    Inventors: Joseph P. Vacca, Dansu Li, Sarah Bettigole
  • Patent number: 10392367
    Abstract: Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: August 27, 2019
    Assignee: Quentis Therapeutics, Inc.
    Inventors: Joseph P. Vacca, Dansu Li, Sarah Bettigole
  • Publication number: 20190240203
    Abstract: The present invention includes novel 3,6-diazabicyclo[3.1.1]heptane antibiotic compounds and any salts or solvates thereof. The present invention further includes methods of preparing such compounds, and methods of treating bacterial infection in a subject using such compounds.
    Type: Application
    Filed: October 20, 2017
    Publication date: August 8, 2019
    Applicant: THE BROAD INSTITUTE, INC.
    Inventor: JOSEPH P. VACCA
  • Publication number: 20190169160
    Abstract: Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.
    Type: Application
    Filed: November 8, 2018
    Publication date: June 6, 2019
    Inventors: Joseph P. VACCA, Dansu LI, Sarah BETTIGOLE
  • Patent number: 10208064
    Abstract: The present invention provides compounds of Formula (I) and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: February 19, 2019
    Inventors: Alexander Pasternak, Ian Davies, Fa-Xiang Ding, Jinlong Jiang, Shuzhi Dong, Xin Gu, Takao Suzuki, Joseph P. Vacca, Zhifa Pu, Shouning Xu
  • Publication number: 20190016706
    Abstract: Described herein are IRE1? inhibitors, compositions containing such inhibitors, and methods of treatment that include administration of such compounds. Exemplary compounds are provided throughout the application.
    Type: Application
    Filed: August 29, 2018
    Publication date: January 17, 2019
    Inventors: Laurie H. Glimcher, Sarah Elizabeth Bettigole, Juan Rodrigo Cubillos-Ruiz, Joseph P. Vacca
  • Publication number: 20180346447
    Abstract: Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.
    Type: Application
    Filed: May 31, 2018
    Publication date: December 6, 2018
    Inventors: Joseph P. Vacca, Dansu Li, Sarah Bettigole
  • Publication number: 20180346446
    Abstract: Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.
    Type: Application
    Filed: May 31, 2018
    Publication date: December 6, 2018
    Inventors: Joseph P. VACCA, Dansu LI, Sarah BETTIGOLE
  • Patent number: 10125123
    Abstract: Described herein are IRE1? inhibitors, compositions containing such inhibitors, and methods of treatment that include administration of such compounds. Exemplary compounds are provided throughout the application.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: November 13, 2018
    Assignee: CORNELL UNIVERSITY
    Inventors: Laurie H. Glimcher, Sarah Elizabeth Bettigole, Juan Rodrigo Cubillos Ruiz, Joseph P. Vacca
  • Publication number: 20180319809
    Abstract: Provided herein are substituted fused quadracyclic compounds useful as inhibitors of MK2. The invention further provides pharmaceutical compositions of the compounds of the invention. The invention also provides medical uses of substituted fused quadracyclic compounds.
    Type: Application
    Filed: July 19, 2018
    Publication date: November 8, 2018
    Inventors: Casey C. McComas, Michael H. Serrano-Wu, Joseph P. Vacca
  • Publication number: 20180305334
    Abstract: Herein, compounds, compositions and methods for modulating inclusion formation and stress granules in cells related to the onset of neurodegenerative diseases, musculoskeletal diseases, cancer, ophthalmological diseases, and viral infections are described.
    Type: Application
    Filed: October 14, 2016
    Publication date: October 25, 2018
    Inventors: Glenn R. Larsen, Manfred Weigele, Joseph P. Vacca, Duane A. Burnett, Amy Ripka
  • Patent number: 10059718
    Abstract: Provided herein are substituted fused quadracyclic compounds useful as inhibitors of MK2. The invention further provides pharmaceutical compositions of the compounds of the invention. The invention also provides medical uses of substituted fused quadracyclic compounds.
    Type: Grant
    Filed: January 3, 2017
    Date of Patent: August 28, 2018
    Assignee: Tabomedex Biosciences, LLC
    Inventors: Casey C. McComas, Michael H. Serrano-Wu, Joseph P. Vacca